Cargando…

Phase 1 Study of Pandemic H1 DNA Vaccine in Healthy Adults

BACKGROUND: A novel, swine-origin influenza A (H1N1) virus was detected worldwide in April 2009, and the World Health Organization (WHO) declared a global pandemic that June. DNA vaccine priming improves responses to inactivated influenza vaccines. We describe the rapid production and clinical evalu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Crank, Michelle C., Gordon, Ingelise J., Yamshchikov, Galina V., Sitar, Sandra, Hu, Zonghui, Enama, Mary E., Holman, LaSonji A., Bailer, Robert T., Pearce, Melissa B., Koup, Richard A., Mascola, John R., Nabel, Gary J., Tumpey, Terrence M., Schwartz, Richard M., Graham, Barney S., Ledgerwood, Julie E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4401709/ https://www.ncbi.nlm.nih.gov/pubmed/25884189 http://dx.doi.org/10.1371/journal.pone.0123969

Ejemplares similares

Phase I Randomized Clinical Trial of VRC DNA and rAd5 HIV-1 Vaccine Delivery by Intramuscular (IM), Subcutaneous (SC) and Intradermal (ID) Administration (VRC 011)
por: Enama, Mary E., et al.
Publicado: (2014)

DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials
por: Ledgerwood, Julie E, et al.
Publicado: (2011)

An avian influenza H7 DNA priming vaccine is safe and immunogenic in a randomized phase I clinical trial
por: DeZure, Adam D., et al.
Publicado: (2017)

A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial
por: Martin, Julie E., et al.
Publicado: (2008)

Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults
por: Gaudinski, Martin R., et al.
Publicado: (2018)

P14-10. Comparable immunogenicity of VRC DNA and rAd5 HIV-1 vaccines delivered by intramuscular, subcutaneous and intradermal routes in healthy adults (VRC 011)
por: Ledgerwood, JE, et al.
Publicado: (2009)

DNA Vaccine Delivered by a Needle-Free Injection Device Improves Potency of Priming for Antibody and CD8+ T-Cell Responses after rAd5 Boost in a Randomized Clinical Trial
por: Graham, Barney S., et al.
Publicado: (2013)

Safety and Immunogenicity of DNA Vaccines Encoding Ebolavirus and Marburgvirus Wild-Type Glycoproteins in a Phase I Clinical Trial
por: Sarwar, Uzma N., et al.
Publicado: (2015)

Safety and Immunogenicity of a rAd35-EnvA Prototype HIV-1 Vaccine in Combination with rAd5-EnvA in Healthy Adults (VRC 012)
por: Crank, Michelle C., et al.
Publicado: (2016)

Priming Immunization with DNA Augments Immunogenicity of Recombinant Adenoviral Vectors for Both HIV-1 Specific Antibody and T-Cell Responses
por: Koup, Richard A., et al.
Publicado: (2010)

DNA Priming for Seasonal Influenza Vaccine: A Phase 1b Double-Blind Randomized Clinical Trial
por: Ledgerwood, Julie E., et al.
Publicado: (2015)

Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials
por: Gaudinski, Martin R, et al.
Publicado: (2018)

Safety and immunogenicity of investigational seasonal influenza hemagglutinin DNA vaccine followed by trivalent inactivated vaccine administered intradermally or intramuscularly in healthy adults: An open-label randomized phase 1 clinical trial
por: Carter, Cristina, et al.
Publicado: (2019)

DNA vaccine priming for seasonal influenza vaccine in children and adolescents 6 to 17 years of age: A phase 1 randomized clinical trial
por: Houser, Katherine V., et al.
Publicado: (2018)

Homologous Boosting with Adenoviral Serotype 5 HIV Vaccine (rAd5) Vector Can Boost Antibody Responses despite Preexisting Vector-Specific Immunity in a Randomized Phase I Clinical Trial
por: Sarwar, Uzma N., et al.
Publicado: (2014)

P18-06. Increased HIV-specific immunity in HIV-infected individuals vaccinated with a DNA prime, rAd5 boost regimen
por: Casazza, JP, et al.
Publicado: (2009)

P14-12. Safety and tolerability of VRC DNA and rAd5 HIV-1 vaccine delivery by intramuscular, subcutaneous and intradermal administration in healthy adults
por: Enama, ME, et al.
Publicado: (2009)

Author Correction: Next-generation influenza vaccines: opportunities and challenges
por: Wei, Chih-Jen, et al.
Publicado: (2020)

Next-generation influenza vaccines: opportunities and challenges
por: Wei, Chih-Jen, et al.
Publicado: (2020)

Preparing for the Next Influenza Pandemic: The Development of a Universal Influenza Vaccine
por: Crank, Michelle C, et al.
Publicado: (2019)

Use of Hemagglutinin Stem Probes Demonstrate Prevalence of Broadly Reactive Group 1 Influenza Antibodies in Human Sera
por: Yassine, Hadi M., et al.
Publicado: (2018)

Randomized Clinical Trial to Assess the Impact of the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01 on HIV-1 Persistence in Individuals on Effective ART
por: Riddler, Sharon A, et al.
Publicado: (2018)

Myeloid and plasmacytoid dendritic cells transfer HIV-1 preferentially to antigen-specific CD4(+) T cells
por: Loré, Karin, et al.
Publicado: (2005)

Vaccine Development in the Twenty‐First Century: Changing Paradigms for Elusive Viruses
por: Graham, B S, et al.
Publicado: (2009)

Asparagine Substitution at PB2 Residue 701 Enhances the Replication, Pathogenicity, and Transmission of the 2009 Pandemic H1N1 Influenza A Virus
por: Zhou, Bin, et al.
Publicado: (2013)

Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trial
por: Houser, Katherine V., et al.
Publicado: (2022)

Comparative Efficacy of Hemagglutinin, Nucleoprotein, and Matrix 2 Protein Gene-Based Vaccination against H5N1 Influenza in Mouse and Ferret
por: Rao, Srinivas S., et al.
Publicado: (2010)

Accelerated COVID-19 vaccine development: milestones, lessons, and prospects
por: Bok, Karin, et al.
Publicado: (2021)

A comprehensive influenza reporter virus panel for high-throughput deep profiling of neutralizing antibodies
por: Creanga, Adrian, et al.
Publicado: (2021)

Differences in HPV-specific antibody Fc-effector functions following Gardasil® and Cervarix® vaccination
por: Roy, Vicky, et al.
Publicado: (2023)

Publication practices and attitudes towards evidence-based medicine in central Asia
por: Yamshchikov, Galina V, et al.
Publicado: (2013)

P19-57 LB. Gene-based vaccination protects against mucosal infection by a heterologous highly pathogenic SIV isolate in rhesus monkeys
por: Letvin, N, et al.
Publicado: (2009)

HIV integration and T cell death: additional commentary
por: Cooper, Arik, et al.
Publicado: (2013)

Rational Design of an Epstein-Barr Virus Vaccine Targeting the Receptor-Binding Site
por: Kanekiyo, Masaru, et al.
Publicado: (2015)

A Single Mutation in the PB1-F2 of H5N1 (HK/97) and 1918 Influenza A Viruses Contributes to Increased Virulence
por: Conenello, Gina M, et al.
Publicado: (2007)

Single-Dose Mucosal Immunization with a Candidate Universal Influenza Vaccine Provides Rapid Protection from Virulent H5N1, H3N2 and H1N1 Viruses
por: Price, Graeme E., et al.
Publicado: (2010)

Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial
por: Mayer, Kenneth H., et al.
Publicado: (2017)

P15-17. Social media as a tool for engaging and educating audiences around HIV vaccine research and clinical trial participation
por: Sitar, S, et al.
Publicado: (2009)

Activation and lysis of human CD4 cells latently infected with HIV-1
por: Pegu, Amarendra, et al.
Publicado: (2015)

Sowing the Seeds of a Pandemic? Mammalian Pathogenicity and Transmissibility of H1 Variant Influenza Viruses from the Swine Reservoir
por: Pulit-Penaloza, Joanna A., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_4hqeq9qjn7d04dga5g99q5q5al